ArcherDX announced a non-exclusive partnership with Illumina to develop in-vitro diagnostic, or IVD, tests for Archer's planned portfolio of next-generation sequencing, or NGS, -based companion diagnostics. The scope of the agreement includes ArcherDX's future portfolio of IVD tests used to facilitate targeted therapy selection and monitoring of Minimal Residual Disease for the management of patients with solid tumor and blood cancers. The planned IVD tests will empower commercial laboratories, hospitals and health systems to run these assays in their local laboratories worldwide. Under the agreement, ArcherDX will develop IVD tests to run on Illumina's NextSeq 550Dx System. ArcherDX will be responsible for obtaining necessary regulatory approvals for each IVD kit and for their subsequent commercialization. ArcherDX and Illumina entered into a similar agreement for the MiSeq Dx System in 2016.
